Trial intelligence / Profile preview

Anlotinib plus AI followed by sequential anlotinib for first-line recurrent/metastatic soft tissue sarcoma

ChiCTR2100054711Phase 2Recruiting

Sponsor: Shandong Cancer Hospital
Start: Dec 2021
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of anlotinib, doxorubicin and ifosfamide in soft tissue sarcoma (STS), sponsored by Shandong Cancer Hospital. Primary endpoint: Objective response rate. Started Dec 2021; status: recruiting.

Drugs

anlotinibdoxorubicinifosfamide

Conditions

soft tissue sarcoma (STS)

Beyond the preview

Go deeper on ChiCTR2100054711.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2100054711.